Crypto · IPO · Market Intelligence

Clear Signals for Market Momentum

Track IPOs, private companies, and crypto-related market movements in one modern intelligence platform.

Explore Data

sagi habasov

1156 POSTS

Exclusive articles:

SKN | Lucid Capital Markets’ SPAC Illumination Acquisition I Files for $200 Million IPO

Illumination Acquisition I, a special purpose acquisition company sponsored by Lucid Capital Markets, has filed to raise up to $200 million in an initial public...

SKN | Zeta Global Holdings Corp. (ZETA) Strengthens Its Position in AI-Driven Marketing Infrastructure

Zeta Global Holdings Corp. continues to attract investor attention as enterprises deepen spending on data-driven marketing and artificial intelligence. The New York–based technology firm...

SKN | Companhia Paranaense de Energia (ELPC) Draws Investor Attention as Regulated Utility Shares Break Higher

Companhia Paranaense de Energia, commonly known as COPEL, is back in focus after its U.S.-listed shares pushed toward the upper end of their recent...

SKN | Travere Therapeutics Charts Its Post-IPO Path as a Focused Rare Disease Biotech

Travere Therapeutics, Inc. has evolved into a highly specialized public biotechnology company targeting rare kidney and metabolic diseases, positioning itself as a differentiated player...

SKN | UiPath Rewrites the Automation Playbook After Its IPO, Positioning for the Next Phase of Enterprise AI

UiPath Inc. (NYSE: PATH) has evolved significantly since its public market debut, emerging as a central player in enterprise automation as organizations accelerate digital...

Breaking

SKN | American Century Investments Launches Emerging Markets Insights ETF on Nasdaq

Key Points: American Century Investments has launched the Emerging...

SKN | ETF Launches and Hilton’s Nasdaq Transfer Shape November 5 Listings

Key Takeaways: The November 5 IPO calendar listed five...

SKN | American Ventures Acquisition I Cuts Proposed IPO Size by 25% to $75 Million

American Ventures Acquisition I, a blank check company targeting...

SKN | Rezera Sets Terms for $200 Million IPO as GSK Signals Up to $25 Million Investment

Rezera, a clinical-stage biotechnology company developing oral NLRP3 inhibitors...
spot_imgspot_img